NSD2

Across TCGA pan-cancer cohorts, NSD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NSD2 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NSD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NSD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where NSD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.928	0.587	.003	20	view →
LSCC	OS	Median	All	1.000	0.922	.012	12	view →
UCEC	OS	Quartile	III,IV	1.000	0.257	.040	8	view →
PDAC	DFS	Median	All	0.523	0.233	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NSD2–LUAD (DFS)

Open the LUAD breakdown →